



ZEMTM
LIFE



Let's Change the World

The World's First Life-Saving Smartwatch

Pitch Deck 2024



Forward-Looking Statements

Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

**Do you dream
about changing
the world?**

Us too.

**Have you been waiting to get in on the
ground floor of a BIG investment opportunity?**

You just found it, ZEM Life Device.





Are you ok with one more
child dying of **anaphylaxis**?

Are you ok with another father
dying of a **heart attack**?

Are you ok with another daughter, son
or friend dying of an **opioid overdose**?

WE AREN'T EITHER.



Before Penicillin

Widespread infections caused severe pain, limb amputations, and unnecessary death.

Before Defibrillator

Abnormal or stopped heart beats during sudden cardiac arrest, frantic CPR attempts, and unnecessary death.

Before ZEM Life Device

Panicked ER visits, mourning families, and unnecessary death from opioid overdoses, allergic reactions, heart attacks, asthma attacks, septic, cardiogenic and hemorrhagic shock, epilepsy, ketoacidosis, and more.

NO MORE...



A portable 24-hour emergency advanced life support system on your wrist.


Join us on the ground floor investment, as we bring this new life saving device to friends and loved ones around the world.



Opioid Overdoses are a **BIG PROBLEM**

SPOTLIGHT ON FENTANYL

Synthetic opioid **50 to 100 times** more powerful than morphine.



Highly potent, so a small amount can rapidly be deadly.

Nearly **impossible to detect** because it cannot be smelled or tasted.

OPIOIDS OVERDOSES ARE DEADLY

70K+

People died of synthetic opioid overdose in 2021 alone

92%

Drug overdoses are preventable deaths

58%

Increased since 2017

781%

Increased since 1999

WE HAVE LIFE SAVING MEDICINE



Naloxone (also known as Narcan) prevents and reverses the deadly effects of an opioid overdose

but only if it's given in time.

It's not just Opioids,
many conditions pose the risk of...

ADAMS-STOKES SYNDROME **CARDIOGENIC SHOCK** HYPERTENSIVE CRISIS TONIC-CLONIC SEIZURES
CONGESTIVE HEART FAILURE HEMORRHAGIC SHOCK
PREVENTABLE

DEATH
SNAKE BITE (COBRAS, KRAITS, MAMBAS)
PULSELESS VENTRICULAR TACHYCARDIA LIFE-THREATENING ASTHMA

ANAPHYLACTIC SHOCK FERTILITY VENTRICULAR FIBRILLATION
ASYSTOLE/PEA ACUTE CORONARY SYNDROMES STATUS EPILEPTICUS ATRIO-VENTRICULAR HEART BLOCK **SIDS**
ANTICOAGULATION REQUIREMENT SUPRAVENTRICULAR TACHYCARDIA
NERVE GAS SCHIZOPHRENIA
SEPTIC SHOCK VENTRICULAR FIBRILLATION
OTHER IM DRUGS

Millions of people die of these conditions when they don't get treatment in time.

ASYSTOLE/PEA
OPIOID OVERDOSE
ECLAMPSIA
ADAMS-STOKES SYNDROME
PAIN
CONTROL
ANGINA
BRONCHOSPASM
DIABETES
AORTIC DISSECTION

REFRACTORY VENTRICULAR TACHYCARDIA
PERFORMANCE ENHANCEMENT
LONG QT SYNDROME
TORSADES DE POINTES
SUPRA-VENTRICULAR TACHYCARDIA
MYOCARDIAL INFARCTION
THYROID STORM

HEMORRHAGE
ATTACK
HEART
WEIGHT LOSS
BRADYCARDIA
VENTRICULAR FIBRILLATION
ATRIAL FIBRILLATION
ORGANOPHOSPHATE POISONING
PRE-TERM LABOR

IMMEDIATE danger requires IMMEDIATE response

When you or someone you love has a critical need for life-saving medication, every second counts.



- **Emergency rooms** are far away
- **Friend may or may not** have the life saving medicine on hand
- **Patient is incapacitated** and unable to move, think or communicate
- **Friend may not know** what is needed, where to find it, when to give it, how to give it or how much to give.



Getting the right dose in time is life-or-death.

Today, No Comparable Solutions Exist

	Epipen Other Auto Injectors	Trip to the Emergency Room	Vial of Medicine on Hand
Time	Fast	Slow	Fast
Cost	\$	\$\$\$	\$
Skill Needed	Medium	✗	✗
Tracks Vitals	✗	✓ Only Current	✗
Automatic delivery	✗	✗	✗
Portability	✓	✗	✗
Supported Conditions	Only one Concern	All	Only one Concern
Repeatability	Single Use	Single Use	✗



Immediate
\$
✗
✓ Current and History
✓
Used in Daily Life
100s of Concerns
Multi Use

ZEM Life Device Brings Peace of Mind

The world's first life-saving
smartwatch coupling:

“Normal” features of a smart watch:

- ✓ Fitness Tracker
- ✓ Sleep Tracker
- ✓ Time and Notifications
- ✓ Phone Calls, Apps



With Life Saving Features and Functionality:



Automatic critical-need
detection



Automatic emergency
services alert broadcasting



Medical Record and
Data availability





Patent-pending automatic
injection medication
delivery system

How the Device Works

Fully Functional Smartwatch

Medicine Cartridges



- 1 Fill watch with cartridge of most concern**
ie: when hiking in area with venomous snake.
- 2 Vitals tracked constantly**
ie: the device knows your pulse, oxygen saturation, respiratory rate, movement. Optional blood pressure and EKG detection.
- 3 Critical-need detection**
ie: detected vital sign changes even if you are incapacitated.
- 4 Medication delivery system**
ie: antidote injected
- 5 Emergency services alert broadcasting**
ie: GPS coordinates sent and emergency services called. Includes downloadable vital history.
- 6 ANOTHER SAVED LIFE**

Love, Pain, and Purpose

ZEM Life Device Co was developed in the aftermath of impossible personal loss and an all too common tragedy:

23-year-old Zachary Ernest Muth was a loving son, a caring boyfriend, a student, a hard-working athlete. After a hockey injury and in need of a rotator cup replacement, **he took a pill** and went to sleep.

The pill was **laced with fentanyl**. If someone known, had someone been there and monitoring his vitals, he could have been saved by a simple dose of Narcan.



Early in the morning of February 1st 2021, **Zachary Ernest Muth** passed away due to an **accidental overdose**.



We are on a mission to make something good out of this to mitigate unexpected death.

We have the drive, tenacity, and experience to make ZEM Life Device a success and save lives.

Our Dedicated Team


All directors are deeply committed and working on ZEM and are doing so for minimum wage.



Steve Muth

VP Business Development

- Participated in over \$1 billion in capital raises.
- Placeholder for 1-2 sentence bio



Joanna D Meston

President


- MD of Anesthesiology
- Successful Patents
- Unique Chemical Engineering background



Zachary S Westerfield

VP Legal

- PC
- Litigation is 50 different cases
- Placeholder for 1-2 sentence bio



Dave Palan, CPA

CFO

- Placeholder for 1-2 sentence bio



Chris Sawyer

VP

- Engineering
- BS ME
- Placeholder for 1-2 sentence bio



Dr. Katherine Compton DO

Executive Director

- A top 5280 and national recognized provider with CU Health.
- Placeholder for 1-2 sentence bio



Dan Ernest PC

Executive Director

- Graduated at New York Law and a Yale university graduate.
- Placeholder for 1-2 sentence bio



Andre Daylan

Executive Director


- Head of new applications
- Texas A&M

Supported by Experienced Advisors



**Andrew
Graff**
Patents

- Leyendecker & Lemire, LLC
- Patent attorney



**Dr. Anna
Budde**
Market and
Clinical Testing

- Head Anesthesiologist at University of Minnesota
- MD of Anesthesiology



**Dr. Kevin
Brady**
Clinical studies

- Head of military Medical Applications
- Placeholder



**Dr. Diane
Gill**
Clinical studies

- Bio or information needed here



Key Partnerships



Prestigious Non-dilutive grant application writers

ZEM Life passed rigorous criteria to be admitted into their program.



“Grant Engine recommends ZEM Life Device Co. to investors seeking to support a company with the potential to make a significant impact on public health and safety. We are hopeful that ZEM Life Device Co. will innovate and lead in the field of medical device development.”
Sam Tetlow



Regulatory compliance consulting services

FDA approval for device



“We have a very high interest in emerging technologies for saving lives from opioid overdoses and deaths. I look forward to continuing our productive relationship with ZEM Life. I urge full financial support for this life saving medical device application.”
Kelly Elliott RN, MS

Significant Traction in just 2.5 Years

2021

- **November 24**
Idea created through difficulty and an unlikely event.
- **December**
Engineering team determined that the functionality of the device idea could be feasible and implemented.
US Provisional application number 63-294,184 filed.

2022

- **January - November**
Full patent and engineering feasibility and design.
- **December**
Full patent application filed
US18/089,656

2023

- **Secured QubeC.3**
Development of device to meet FDA requirements
- **Secured Eminence Clinical**
Research for FDA assistance
- **June**
Received full patent pending status
US20230201463A1
- **September**
Filed FDA Breakthrough Device application
- **October**
Secured CF Offering with Reg D company
- **December**
Filed corporation in Delaware


2024

- **January**
High level plan for FDA completion
Secured Grant Engine for grant capital
- **March**
Filed additional patent addendums
- **April**
Engaged all Executive Directors at Min wage
Filed SBIR Phase I application 4-24
- **May**
Completed SEC - CR offering agreements

Lucrative Business Model


Proprietary Device

Single purchase



Software-Enabled Cartridges

Consumable, repeat purchase
Specific software/code for EACH condition and drug (and we own the IP)



BUSINESS MODEL OPTIONS

- 1 Branded cartridges - licensing deals or partnerships with drug manufacturers
- 2 Generic cartridges filled at the pharmacy
- 3 User-refillable cartridges



FASTER TIME-TO MARKET

Because all drugs are currently FDA approved for IM and SubQ delivery, **there will be less strict FDA testing and approvals required for our cartridges**

Expanded Product Offerings Planned

TYPES OF CARTRIDGES

“Jet” injection

Less invasive air injection

Needle injection


1st Cartridge for Narcan will be this type for faster speed to market with FDA

High battery Cartridge

For travel, military needs

Reloadable Cartridge

For daily use injections



TYPES OF DELIVERY

Automatic

(Triggered when body readings indicates a need)

Remote

Triggered by a 3rd Party

- Doctor >>> patient
- Parent >>> child
- General >>> military personnel
- Police transport >>> prisoner

Vast Market Opportunity

The potential applications are so vast, that is is hard to quantify all potential opportunities.
These are just a few.

OPIOIDS



80,411 Deaths
Opioid overdose in 2021

16.95M Doses of Naloxone
Distributed in the U.S. in 2021.

HEART ATTACK



695K Deaths
In the U.S. from heart disease in 2021

16.3M Americans
aged 20+ have Coronary heart disease

ANAPHYLACTIC SHOCK



1 in 50 Americans

Have anaphylaxis, a life-threatening allergic reaction

SEPSIS



~1.7M Adults
Develop sepsis in the U.S.

~270K Die
3rd leading cause of death in U.S. hospitals

EPILEPSY

3.4M people
Have epilepsy

8M Aprox
EpiPens sold each year



~\$2.4B
In revenues



Future Opportunities

INFANTS



An infant device worn around the foot

SIDS

Apnea

Temperature monitoring

ANIMALS



An animal device with many opportunities

Endangered animals

Fertility for specialty breeding animals

Antibiotic deliver

MILITARY



An remotely monitored version worn by soldiers

Antidote for nerve gas

Morphine for pain and shock relief

Staying awake for long missions

Financial Projections


BASED ON THE THE FIRST CARTRIDGE OPIATE (NARCAN)



Wearable Devices - Licensing



Cartridges - Licensing



Key Assumptions

\$5.0M

Initial crowdfunding raise

\$20M


Expected in revenue in 2029



Positive cashflow anticipated in year 1

Financial Projections


BASED ON THE LONG-TERM PLAN WITH ALL CARTRIDGES AND DEVICE MARKET OPPORTUNITIES



Wearable Devices - Licensing



Cartridges - Licensing



Key Assumptions

Multiple founding

Rounds achieved, including all warrants and offerings

\$115M

Expected in revenue in 2029



Margins are based on partnership model

FIRST OFFERING

Seeking Funding to Launch Initial Cartridge

RAISING
**Up to
\$5M**

● **Develop partnerships for the medications**

● **Development of device ready for full manufacturing**

● **FDA approvals**

- Watch approved as a medical device
- Leverage watch approval for more seamless cartridge approval

Funding will prepare us to go to market:



Fully working device



Initial cartridge(s)

FDA

Device is logged with FDA



Early marketing

Now is the Time to Invest

3 additional offerings--at higher valuations--planned in the next 2 years after meeting initial goals.

About the Offering

KEY OFFERING DETAILS

~40% of the company for \$5M.

Capitalization and dilution is minimal.

Convertible preferred.

Three different closes:

1 st Tranche	2 nd Tranche	3 rd Tranche
3 warrants	2 warrants	1 warrant

YOUR INVESTMENT



\$50

Minimum investment

\$150,000

Maximum investment

**For larger investments, strategic partnership will be required for stock availability.*

INVESTOR PERKS

\$100+

"I helped saved the world" T-shirt

Other perks to TBD

\$250+

Access to the kick off party

Other perks to TBD

\$1K+

Other perks to TBD

\$2.5K+

Other perks to TBD

\$25K+

Other perks to TBD

About



This small residual income will be used to support the good work the foundation will do:

Sharing this technology with the world through a HUMANITARIAN model.

Opening a healing center for anyone dealing with devastating loss or pain.



Palms 23 Foundation is a nonprofit that owns a royalty for the IP smartwatch device and medication delivery system.



ZEM Life Device has the exclusive right to license the IP. Full office, manufacturing and warehouse availability with a Palms location.



PALMS23
Website



Together Let's Change the World

Now is the time to stop
unexpected death.

Or, please share this with
someone else who can help.



Subscribe Now





Thanks for your support from all of us at
ZEM LIFE DEVICE CO.

To learn more about investing
Reach out to investorfamily@zemlifedevic.com



Learn More

www.zemlifedevic.com

Forward-Looking Statements

Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.